简体中文|English
检索试验 按国家、省（市）统计 按疾病代码统计 按试验实施单位统计 按试验主办单位统计 按经费或物资来源统计 按征募研究对象情况统计 按注册状态统计 按干预措施统计 按伦理委员会统计 按研究类型统计
利丙双卡因乳膏在健康受试者中的单剂量、空腹、随机、开放、两周期、两交叉生物等效性研究
下载XML文档

注册号：

Registration number：

 ChiCTR2200055373 

最近更新日期：

Date of Last Refreshed on：

 2023-01-29 21:41:57 

注册时间：

Date of Registration：

 2022-01-08 00:00:00 

注册号状态：

预注册

Registration Status：

Prospective registration

注册题目：

利丙双卡因乳膏在健康受试者中的单剂量、空腹、随机、开放、两周期、两交叉生物等效性研究

Public title：

A single-dose, fasting, randomized, open-label, two-cycle, two-crossover bioequivalence study of riprobicaine cream in healthy subjects

注册题目简写：

English Acronym：

研究课题的正式科学名称：

利丙双卡因乳膏在健康受试者中的单剂量、空腹、随机、开放、两周期、两交叉生物等效性研究

Scientific title：

A single-dose, fasting, randomized, open-label, two-cycle, two-crossover bioequivalence study of riprobicaine cream in healthy subjects

研究课题代号(代码)：

Study subject ID：

在二级注册机构或其它机构的注册号：

The registration number of the Partner Registry or other register：

申请注册联系人：

孙泽旭 

研究负责人：

阳国平/项玉霞 

Applicant：

Sun Zexu 

Study leader：

Yang Guoping, Xiang Yuxia 

申请注册联系人电话：

Applicant telephone：

 +86 19375180485

研究负责人电话：

Study leader's
telephone：

+86 731 89918665

申请注册联系人传真 ：

Applicant Fax：

研究负责人传真：

Study leader's fax：

申请注册联系人电子邮件：

Applicant E-mail：

 133110704@qq.com

研究负责人电子邮件：

Study leader's E-mail：

 ygp9880@126.com

申请单位网址(自愿提供)：

Applicant website(voluntary supply)：

研究负责人网址(自愿提供)：

Study leader's website(voluntary supply)：

申请注册联系人通讯地址：

湖南省长沙市岳麓区桐梓坡路138号

研究负责人通讯地址：

湖南省长沙市岳麓区桐梓坡路138号

Applicant address：

138 Tongzipo Road, Yuelu District, Changsha, Hu'nan

Study leader's address：

138 Tongzipo Road, Yuelu District, Changsha, Hu'nan

申请注册联系人邮政编码：

Applicant postcode：

研究负责人邮政编码：

Study leader's postcode：

申请人所在单位：

中南大学湘雅三医院临床试验研究中心

Applicant's institution：

The Third Xiangya Hospital of Central South University

研究负责人所在单位：

Affiliation of the Leader：

是否获伦理委员会批准：

是

Approved by ethic committee：

Yes

伦理委员会批件文号：

Approved No. of ethic committee：

 21272

伦理委员会批件附件：

Approved file of Ethical Committee：

 查看附件View

批准本研究的伦理委员会名称：

中南大学湘雅三医院伦理委员会

Name of the ethic committee：

The Third Xiangya Hospital of Central South University Ethics Committee

伦理委员会批准日期：

Date of approved by ethic committee：

 2021-12-14 00:00:00

伦理委员会联系人：

王晓敏

Contact Name of the ethic committee：

Wang Xiaomin

伦理委员会联系地址：

湖南省长沙市岳麓区桐梓坡路138号中南大学湘雅三医院伦理委员会

Contact Address of the ethic committee：

138 Tongzipo Road, Yuelu District, Changsha, Hu'nan

伦理委员会联系人电话：

Contact phone of the ethic committee：

伦理委员会联系人邮箱：

Contact email of the ethic committee：

研究实施负责（组长）单位：

中南大学湘雅三医院临床试验研究中心

Primary sponsor：

The Third Xiangya Hospital of Central South University

研究实施负责（组长）单位地址：

湖南省长沙市岳麓区桐梓坡路138号

Primary sponsor's address：

138 Tongzipo Road, Yuelu District, Changsha, Hu'nan

试验主办单位(项目批准或申办者)：

Secondary sponsor：

国家：

中国

省(直辖市)：

湖南

市(区县)：

长沙

Country：

China

Province：

Hu'nan

City：

Changsha

单位(医院)：

中南大学湘雅三医院临床试验研究中心

具体地址：

岳麓区桐梓坡路138号

Institution
hospital：

The Third Xiangya Hospital of Central South University

Address：

138 Tongzipo Road, Yuelu District

经费或物资来源：

长沙晶易医药科技股份有限公司

Source(s) of funding：

Changsha Jingyi Pharmaceutical Technology Co., Ltd.

研究疾病：

N/A  

Target disease：

N/A

研究疾病代码：

Target disease code：

研究类型：

干预性研究

Study type：

Interventional study

研究所处阶段：

 I期临床试验 

Study phase：

1

研究设计：

随机交叉对照 

Study design：

Cross-over 

研究目的：

1.主要研究目的：本研究以河北亚东制药有限公司生产的利丙双卡因乳膏 5 g（1 g：利多卡因 25mg 和丙胺卡因 25mg）为受试制剂，以 AstraZeneca GmbH 生产的利丙双卡因乳膏 5 g（1 g：利多卡因 25 mg 和丙胺卡因 25 mg，商品名：EMLA）为参比制剂，评价受试制剂和参比制剂在空腹条件下给药时的生物等效性。 2.次要研究目的：观察受试制剂和参比制剂在健康受试者中的安全性。  

Objectives of Study：

1. Main research purposes: In this study, lipocaine cream 5 g (1 g: lidocaine 25mg and prilocaine 25mg) produced by Hebei Yadong Pharmaceutical Co., Ltd. was used as the test preparation, and the lipocaine cream 5 g (1 g: lidocaine 25 mg and prilocaine 25 mg, trade name: EMLA) produced by AstraZeneca GmbH was used as the reference preparation, to evaluate the bioequivalence of the test and reference formulations when administered under fasting conditions. 2. Secondary research purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.

药物成份或治疗方案详述：

 

Description for medicine or protocol of treatment in detail：

 

纳入标准：

Inclusion criteria

排除标准：

1.试验前 3 个月内参加过其他任何临床试验者；
2.对利多卡因、丙胺卡因等酰胺类局部麻醉药、本品中任何辅料或医用胶带过敏者，或对两种或两种以上药物（或食物）过敏者；
3.存在研究者判断为有临床意义的心血管（心律失常等）、肝脏、肾脏、内分泌、消化道、血液系统、呼吸系统、恶性肿瘤、精神异常、严重感染等病史或现有上述疾病者；
4.患有研究者判断为有临床意义的皮肤疾病（如：湿疹、荨麻疹、特异性皮炎等）者，或给药部位（双侧大腿前侧皮肤）有胎记、疤痕、纹身，开放性伤口者，或毛发旺盛者；
5.既往存在或现有葡萄糖-6-磷酸脱氢酶缺乏症、高铁血红蛋白血症者（问诊）；
6.有体位性低血压、晕针或晕血病史或静脉穿刺采血不耐受者；
7.试验前 4 周内接受过外科手术者，或者计划在研究期间进行手术者，且研究者判断会影响药物吸收、分布、代谢、排泄；
8.研究首次用药前 3 个月内献血或失血≥400 mL，或计划在研究期间或研究结束后 3 个月内献血或血液成分者；
9.筛选前 4 周内使用过任何与利多卡因、丙胺卡因有相互作用的药物（如 III 类抗心律失常药（胺碘酮）、西咪替丁或 β 受体阻滞剂等）或与高铁血红蛋白诱导药物有关的药物（如磺酰胺、硝基呋喃妥因、苯妥英钠、苯巴比妥等）者，或筛选前 4 周内双侧大腿前侧皮肤使用了外用皮肤科药物治疗者；
10.筛选前 1 个月内接受过灭活疫苗接种，筛选前 3 个月内接受过活/减毒疫苗接种或计划在试验期间接受灭/活/减毒疫苗接种者；
11.试验前 14 天内使用过任何处方药（疫苗除外）、非处方药、中草药、保健品者；
12.试验前 3 个月内饮用过量（一天 8 杯以上，1 杯=200 mL）茶、咖啡或含咖啡因的饮料者；或研究首次用药前 48 h 内，摄入任何含有咖啡因的食物或饮料（如咖啡、浓茶、巧克力等）者；
13.试验前 3 个月平均每日吸烟量多于 5 支者，以及入选后至整个试验期间不能接受禁止吸烟者；
14.试验前 6 个月内经常饮酒者，即每周饮酒超过 14 单位酒精（1 单位=360 mL 啤酒或45 mL 酒精量为 40%的烈酒或 150 mL 葡萄酒）；或试验期间不愿意停止饮酒或任何含酒精的制品；
15.不能遵守统一饮食（如对标准餐食物不耐受等）者；
16.药物滥用者或试验前 3 个月使用过软毒品（如：大麻）或试验前 1 年服用硬毒品（如：可卡因、苯环己哌啶等）者；
17.妊娠或哺乳期妇女，以及男性或女性受试者（或其伴侣）在入选后至试验结束后 3 个月内不愿意或不能采取一种或一种以上有效避孕措施；
18.生命体征异常者（收缩压<90 mmHg 或>140 mmHg，舒张压<50 mmHg 或>90 mmHg；心率<50 bpm 或>100 bpm）或体格检查、心电图、实验室检查异常有临床意义（以临床研究医生判断为准）；
19.研究者认为存在任何可能影响受试者提供知情同意或遵循试验方案的情况，或受试者参加试验可能影响试验结果或自身安全；
20.除上述注明的入住期问诊项，符合下列条件之一也应排除：
（1）自上次离院后至入住前有伴随用药、急性疾病且经研究者判断对试验结果有影响者；
（2）自上次离院后至入住前服用烟草制品或服用过含有酒精的制品且经研究者判断对试验结果有影响者；
（3）自上次离院后至入住前饮用茶、咖啡或含咖啡因的饮料且经研究者判断对试验结果有影响者；
（4）自上次离院后至入住前发生非保护性行为者；
（5）用药前 48 h 内，摄入过任何富含黄嘌呤或葡萄柚成份或其他影响药物吸收、分布、代谢、排泄等的饮料或食物者；
（6）生命体征异常有临床意义且研究者认为无法再继续参加试验者；
（7）药物滥用筛查（吗啡、甲基安非他明、氯胺酮、二亚甲基双氧安非他明、四氢大麻酚酸）试验阳性者；
（8）酒精呼气测试结果>0.0 mg/100 mL 者；
（9）女性血妊娠检查异常且有临床意义者；
（10）给药部位（双侧大腿前侧皮肤）有异常者；
（11）受试者可能因为其他原因而不能完成本研究或经研究者判断具有其它不宜参加试验原因者。

Exclusion criteria：

1. Those who have participated in any other clinical trials within 3 months before the trial;
2. Those who are allergic to amide local anesthetics such as lidocaine and prilocaine, any excipients in this product or medical tape, or those who are allergic to two or more drugs (or foods);
3. There is a history of cardiovascular (arrhythmia, etc.), liver, kidney, endocrine, digestive tract, blood system, respiratory system, malignant tumor, mental abnormality, serious infection, etc. judged by the investigator to be clinically significant, or those who have the above diseases ;
4. Patients with skin diseases (such as eczema, urticaria, atopic dermatitis, etc.) judged by the researchers to be clinically significant, or there are birthmarks, scars, tattoos, open wounds, or exuberant hair at the administration site (the skin on the front of both thighs);
5. Patients with previous or existing glucose-6-phosphate dehydrogenase deficiency and methemoglobinemia (inquiry);
6. Those with orthostatic hypotension, history of acupuncture or haemorrhage, or intolerance to venipuncture blood collection;
7. Those who have undergone surgery within 4 weeks before the trial, or those who plan to undergo surgery during the study period, and the investigator judges that it will affect the absorption, distribution, metabolism, and excretion of the drug;
8. Those who donate blood or lose >=400 mL of blood within 3 months before the first drug use in the study, or plan to donate blood or blood components during the study period or within 3 months after the end of the study;
9. Use of any drug that interacts with lidocaine, prilocaine (such as class III antiarrhythmic drugs (amiodarone), cimetidine or beta-blockers, etc.) or drugs related to methemoglobin-inducing drugs (such as sulfonamide, nitronitrofurantoin, phenytoin, phenobarbital, etc.) within 4 weeks before screening, or those who have been treated with topical dermatological drugs on the skin of bilateral front thighs within 4 weeks before screening;
10. Those who received inactivated vaccine within 1 month before screening, received live/attenuated vaccine within 3 months before screening or planned to receive inactivated/live/attenuated vaccine during the trial;
11. Those who have used any prescription drugs (except vaccines), non-prescription drugs, Chinese herbal medicines, and health products within 14 days before the test;
12. Those who drink too much (more than 8 cups a day, 1 cup = 200 mL) tea, coffee or caffeinated beverages within 3 months before the test; or those who ingest any food or drink containing caffeine (such as coffee, strong tea, chocolate, etc.) within 48 hours before the first dose of the study;
13. Those with an average daily smoking volume of more than 5 cigarettes in the first 3 months of the trial, and those who cannot accept smoking bans after enrollment to the entire trial period;
14. Frequent drinkers within 6 months before the test, that is, drinking more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of spirits with an alcohol content of 40% or 150 mL of wine); or unwillingness to stop drinking alcohol or any alcoholic products during the trial;
15. Those who cannot comply with a unified diet (such as intolerance to standard meals, etc.);
16. Drug abusers or those who have used soft drugs (such as marijuana) in the 3 months before the test or hard drugs (such as cocaine, phencyclidine, etc.) in the 1 year before the test;
17. Pregnant or lactating patients, and patients (or their partners) are unwilling or unable to take one or more effective contraceptive measures within 3 months after enrollment to the end of the trial;
18. Abnormal vital signs (systolic blood pressure <90 mmHg or >140 mmHg, diastolic blood pressure <50 mmHg or >90 mmHg; heart rate <50 bpm or >100 bpm) or abnormal physical examination, electrocardiogram and laboratory tests have clinical significance (patient to the judgment of the clinical research doctor);
19. The investigator believes that there are any circumstances that may affect the patient's providing informed consent or following the trial protocol, or that the patient's participation in the trial may affect the trial results or their own safety;
20. In addition to the above-mentioned items for consultation during the stay period, one of the following conditions should also be excluded:
(1) Those who have concomitant medication or acute disease from the last time they were discharged from the hospital to before admission, and who have been judged by the investigator to have an impact on the test results;
(2) Those who have taken tobacco products or alcohol-containing products since the last time they were discharged from the hospital and before admission, and who have been judged by the investigator to have an impact on the test results;
(3) Those who drank tea, coffee or caffeinated beverages from the last time they were discharged from the hospital to before admission and judged by the investigator to have an influence on the test results;
(4) Those who have had unprotected sexual behavior since the last time they were discharged from the hospital and before admission;
(5) Those who have ingested any beverages or foods rich in xanthine or grapefruit or other beverages or foods that affect the absorption, distribution, metabolism, and excretion of drugs within 48 hours before taking the drug;
(6) Abnormal vital signs are clinically significant and the investigator believes that they can no longer participate in the trial;
(7) Positive test for drug abuse screening (morphine, methamphetamine, ketamine, MDMA, THC);
(8) Alcohol breath test results > 0.0 mg/100 mL;
(9) Women with abnormal blood pregnancy test and clinical significance;
(10) Abnormalities at the administration site (front skin of both thighs);
(11) Patients may not be able to complete the study due to other reasons or have other reasons judged by the investigator to be unsuitable to participate in the trial.

研究实施时间：

Study execute time：

从 From 2022-02-01 00:00:00至 To 2022-12-31 00:00:00  

征募观察对象时间：

Recruiting time：

从 From 2022-02-01 00:00:00 至 To 2022-12-31 00:00:00

干预措施：

Interventions：

组别：

T组

样本量：

 15

Group：

Group T

Sample size：

干预措施：

先给受试制剂再给参比试剂

干预措施代码：

Intervention：

Give the test preparation first and then the reference reagent

Intervention code：

组别：

R组

样本量：

 15

Group：

Group R

Sample size：

干预措施：

先给参比试剂再给受试制剂

干预措施代码：

Intervention：

Give the reference reagent first and then the test product

Intervention code：

研究实施地点：

Countries of recruitment and research settings：

国家：

 中国

省(直辖市)：

 湖南 

市(区县)：

 长沙 

Country：

China

Province：

Hu'nan

City：

Changsha

单位(医院)：

 中南大学湘雅三医院 

单位级别：

 三级甲等 

Institution
hospital：

The Third Xiangya Hospital of Central South University

Level of the institution：

Tertiary A

测量指标：

Outcomes：

指标中文名：

血药浓度

指标类型：

主要指标

Outcome：

plasma concentration

Type：

Primary indicator

测量时间点：

测量方法：

Measure time point of outcome：

Measure method：

采集人体标本：

Collecting sample(s)
from participants：

标本中文名：

血液

组织：

Sample Name：

Blood

Tissue：

人体标本去向

 使用后销毁  

说明

Fate of sample：

Destruction after use  

Note：

征募研究对象情况：

Recruiting status：

尚未开始

Not yet recruiting

年龄范围：

Participant age：
最小 Min age 18 岁 years
最大 Max age 60 岁 years

性别：

男女均可

Gender：

Both

随机方法（请说明由何人用什么方法产生随机序列）：

本研究采用区组随机方法，组间比例 1:1，让每位受试者随机的的进入（T-R）组或（R-T）组。

Randomization Procedure (please state who generates the random number sequence and by what method)：

In this study, the method of block randomization was adopted, and the ratio between groups was 1:1. Each subject was randomly entered into (T-R) group or (R-T) group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法：

开放

Blinding：

Open-label

是否共享原始数据：

IPD sharing

否No

共享原始数据的方式（说明：请填入公开原始数据日期和方式，如采用网络平台，需填该网络平台名称和网址）：

Not stated 请阅读注册指南中关于 共享原始数据 的内容。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url)：

Not stated

数据采集和管理（说明：数据采集和管理由两部分组成，一为病例记录表(Case Record Form, CRF)，二为电子采集和管理系统(Electronic Data Capture, EDC)，如ResMan即为一种基于互联网的EDC：

本次试验数据管理采用电子数据采集系统（EDC），由浙江太美医疗科技股份有限公司提供电子数据采集系统（eCollect ? V5），具体内容详见“数据管理计划”。数据管理计划：由数据经理撰写，作为整个数据管理过程的指导性文件，数据管理所有过程均应按照计划进行操作。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture：

Electronic Data Acquisition system (EDC) was used for data management in this study. ECollect ? V5 was provided by Zhejiang Taimei Medical Technology Co.LTD. Please refer to "Data Management Plan" for details. Data management plan: it is written by the data manager and serves as a guiding document for the entire data management process. All data management processes should follow the plan.

数据与安全监察委员会：

Data and Safety Monitoring Committee：

暂未确定/Not yet

注册人：

Name of Registration：

  2022-01-08 07:53:23
返回列表
欢迎访问WHO国际临床试验注册平台 Clinical Trials Hong Kong

中国临床试验注册中心 - 世界卫生组织国际临床试验注册平台一级注册机构

Copyright(c) (2005 - 2023) Chictr.org.cn.All rights reserved. 中国临床试验注册中心 版权所有

蜀ICP备16010396号-9

提示：推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统